| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
10% Owner | Former 10% Owner
1 company
Euclidean Capital LLC last filed a Form 4 in June 2021, as 10% Owner at PMVP.
Our model assigns Euclidean Capital LLC a strong insider score of 82/100, based on 6 past trades. Over a 12-month horizon, all 6 of those trades were profitable, with an average 12-month return of +70.0%.
At the last filing, the largest reported position was 127,099 shares of PMVP. The PMVP filings lean toward selling, a net 189,112 shares.
Euclidean Capital LLC has 4 Form 4 filings on record from September 2020 to June 2021, all as 10% Owner at PMV Pharmaceuticals (PMVP), 2020–2021.
The 34 reported transactions were 30 open-market sales and 4 conversions.
Counted by filing, the open-market trades come to no purchases and 3 sales worth about $6.4M.
The largest open-market sale was 66,396 shares of PMVP at an average $34.01 on June 14, 2021, about $2.3M. Twelve months later PMVP was down 72%.
Shares as reported in the last Form 4 for each company; the most recent is from June 2021. Values use today's prices. Any trades after the last filing were not reported, so current holdings may differ.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Jun 14, 2021 | PMVP Pmv Pharmaceuticals, Inc. | 10% Owner | Sell | 66,396 | $34.01 | $2,257,954.69 | -34.3% | -16.5% | -72.3% | |
| Jun 10, 2021 | PMVP Pmv Pharmaceuticals, Inc. | 10% Owner | Sell | 60,271 | $33.31 | $2,007,708.76 | -31.7% | -12.1% | -70.5% | |
| Jun 8, 2021 | PMVP Pmv Pharmaceuticals, Inc. | 10% Owner | Sell | 62,445 | $33.50 | $2,091,787.14 | -32.3% | -13.0% | -69.1% |